ATE408688T1 - Polypeptide zur modulierung des überlebens von zellen - Google Patents

Polypeptide zur modulierung des überlebens von zellen

Info

Publication number: ATE408688T1
Authority: AT; Austria
Prior art keywords: death; p75ntr; cell survival; present; well
Prior art date: 1998-10-06

Application number

AT99953434T

Other languages

English (en)

Inventor

Perry Bartlett

Elizabeth Coulson

Katrina Fieldew

Manuel Baca

Trevor Kilpatrick

Cheema Surindar

Original Assignee

Univ Queensland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-06

Filing date

1999-10-05

Publication date

2008-10-15

1998-10-06 Priority claimed from AUPP6353A external-priority patent/AUPP635398A0/en

1998-10-07 Priority claimed from AUPP6351A external-priority patent/AUPP635198A0/en

1999-06-01 Priority claimed from AUPQ0701A external-priority patent/AUPQ070199A0/en

1999-10-05 Application filed by Univ Queensland filed Critical Univ Queensland

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE408688T1 publication Critical patent/ATE408688T1/de

Links

230000004083 survival effect Effects 0.000 title abstract 6
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
229920001184 polypeptide Polymers 0.000 title abstract 2
102000007339 Nerve Growth Factor Receptors Human genes 0.000 abstract 6
108010032605 Nerve Growth Factor Receptors Proteins 0.000 abstract 6
210000004027 cell Anatomy 0.000 abstract 6
230000034994 death Effects 0.000 abstract 6
230000011664 signaling Effects 0.000 abstract 4
230000030833 cell death Effects 0.000 abstract 3
230000001404 mediated effect Effects 0.000 abstract 2
230000001737 promoting effect Effects 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
210000003061 neural cell Anatomy 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000009131 signaling function Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT99953434T 1998-10-06 1999-10-05 Polypeptide zur modulierung des überlebens von zellen ATE408688T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AUPP6353A AUPP635398A0 (en)	1998-10-06	1998-10-06	A method of modulating cell survival and reagents useful for same
AUPP6351A AUPP635198A0 (en)	1998-10-07	1998-10-07	A method of modulating cell survival and reagents useful for same-ii
AUPQ0701A AUPQ070199A0 (en)	1999-06-01	1999-06-01	A method of modulating cell survival and reagents useful for same-iii

Publications (1)

Publication Number	Publication Date
ATE408688T1 true ATE408688T1 (de)	2008-10-15

Family

ID=27158107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99953434T ATE408688T1 (de)	1998-10-06	1999-10-05	Polypeptide zur modulierung des überlebens von zellen

Country Status (6)

Country	Link
US (3)	US20020137188A1 (de)
EP (1)	EP1121434B1 (de)
AT (1)	ATE408688T1 (de)
CA (1)	CA2345379C (de)
DE (1)	DE69939593D1 (de)
WO (1)	WO2000020578A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000020578A1 (en)	1998-10-06	2000-04-13	The Walter And Eliza Hall Institute Of Medical Research	A method of modulating cell survival and reagents useful for same
US6472176B2 (en) *	2000-12-14	2002-10-29	Genvec, Inc.	Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
AU2002339213A1 (en) *	2001-08-09	2003-02-24	Genset S.A.	Migenix agonists and antagonists for use in the treatment of metabolic disorders
AU2003222681B8 (en) *	2002-05-14	2009-06-18	The University Of Queensland	A method of treatment
AUPS230702A0 (en) *	2002-05-14	2002-06-13	Walter And Eliza Hall Institute Of Medical Research, The	A method of treatment
DE602005010436D1 (de) *	2004-07-14	2008-11-27	Janssen Pharmaceutica Nv	P75ntr-screeningtest zur identifizierung von modulatoren der apoptose
WO2014049556A2 (en) *	2012-09-28	2014-04-03	The University Of Queensland	Neurotrophin-tyrosine kinase receptor signaling
US10786543B2 (en) *	2015-09-22	2020-09-29	The Johns Hopkins University	P75NTR antagonists and treatment of acute and chronic cardiac disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5606023A (en) *	1994-05-24	1997-02-25	Thomas Jefferson University	Mutant tumor necrosis factor proteins
EP0846169B1 (de) *	1995-08-04	2003-03-19	Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D.	Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
WO2000020578A1 (en)	1998-10-06	2000-04-13	The Walter And Eliza Hall Institute Of Medical Research	A method of modulating cell survival and reagents useful for same
AU772811B2 (en)	1998-10-06	2004-05-06	University Of Queensland, The	A method of modulating cell survival and reagents useful for same

1999
- 1999-10-05 WO PCT/AU1999/000860 patent/WO2000020578A1/en not_active Ceased
- 1999-10-05 EP EP99953434A patent/EP1121434B1/de not_active Expired - Lifetime
- 1999-10-05 DE DE69939593T patent/DE69939593D1/de not_active Expired - Lifetime
- 1999-10-05 AT AT99953434T patent/ATE408688T1/de not_active IP Right Cessation
- 1999-10-05 CA CA2345379A patent/CA2345379C/en not_active Expired - Fee Related
2001
- 2001-03-30 US US09/821,831 patent/US20020137188A1/en not_active Abandoned
2004
- 2004-08-18 US US10/921,065 patent/US7919471B2/en not_active Expired - Fee Related
2010
- 2010-09-17 US US12/885,194 patent/US8299027B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20020137188A1 (en)	2002-09-26
CA2345379A1 (en)	2000-04-13
DE69939593D1 (de)	2008-10-30
EP1121434A1 (de)	2001-08-08
US20050090442A1 (en)	2005-04-28
CA2345379C (en)	2011-12-06
EP1121434B1 (de)	2008-09-17
EP1121434A4 (de)	2005-03-02
US7919471B2 (en)	2011-04-05
US20110172143A1 (en)	2011-07-14
US8299027B2 (en)	2012-10-30
WO2000020578A1 (en)	2000-04-13

Legal Events

Date	Code	Title	Description
2009-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties
2010-01-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DK0888452T3 (da)	2004-06-14	Human CYR61, et ekstracellulært matrix-signalmolekyle
ATE318905T1 (de)	2006-03-15	Homologe des tie-rezeptortyrosinekinase liganden
DK1129190T3 (da)	2007-09-24	Human TSLP DNA og polypeptider
ATE227739T1 (de)	2002-11-15	Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
NO990086D0 (no)	1999-01-08	Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
DK1265914T3 (da)	2008-03-10	WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DK0970213T3 (da)	2007-05-21	Dödsdomæneholdig receptor
AU6250098A (en)	1998-08-18	Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69939593D1 (de)	2008-10-30	Polypeptide zur modulierung des überlebens von zellen
ATE311443T1 (de)	2005-12-15	Methoden zur durchforstung (screenen) von proteinen
ATE391136T1 (de)	2008-04-15	Fas peptide und antikörper zur modulierung von apoptosis
EP1282722A4 (de)	2004-04-07	Stabilisierte proteine
ATE256740T1 (de)	2004-01-15	Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
ATE360643T1 (de)	2007-05-15	Humanes cyr61
ATE259652T1 (de)	2004-03-15	Neuronale verwendungen des bmp-11
ATE464320T1 (de)	2010-04-15	Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE307826T1 (de)	2005-11-15	Oligomere von konformationsbeschränkten, nicht- peptidischen di- oder tripeptid-mimetika, und ihre verwendung zur synthese von künstlichen polypeptiden und proteinen
FI971896A0 (fi)	1997-05-02	BMP-tyyppi II-reseptoria koodaava cDNA
WO2000067793A8 (en)	2001-05-25	Death domain containing receptor 4
WO1999031233A8 (en)	1999-08-12	Polypeptides, polynucleotides and uses thereof
ATE332373T1 (de)	2006-07-15	Menschlisches il-1 epsilon dna und polypeptide
EP1187842A4 (de)	2004-03-03	Der tr10 rezeptor des menschlichen tumor-nekrose-faktors
WO2003074675A3 (en)	2003-12-31	Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
NZ505866A (en)	2003-03-28	V196 (also known as RAMP2) DNA and polypeptides
WO2002077193A8 (en)	2003-03-27	Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof